Suppr超能文献

亚临床甲状腺功能减退患者中同型半胱氨酸和纤维蛋白原随左旋甲状腺素的变化情况。

Homocysteine and fibrinogen changes with L-thyroxine in subclinical hypothyroid patients.

作者信息

Cakal Başak, Cakal Erman, Demirbaş Berrin, Ozkaya Mesut, Karaahmetoğlu Selma, Serter Rüştü, Aral Yalçin

机构信息

Ankara Numune Education and Research Hospital, Department of Internal Medicine, Ankara, Turkey.

出版信息

J Korean Med Sci. 2007 Jun;22(3):431-5. doi: 10.3346/jkms.2007.22.3.431.

Abstract

The aim of the present study was to evaluate plasma total homocysteine (Hcys) and serum fibrinogen concentrations in subclinical hypothyroid (SH) and overt hypothyroid patients before and after L-thyroxine (LT4) replacement and to compare them in euthyroid subjects. Fifteen SH and 20 hypothyroid premenopausal women were recruited in the study. We measured fasting plasma levels of Hcys and serum levels of free thyroxine (fT4), free triiodothyronine (fT3), thyrotropin (TSH), folate, vitamin B12, fibrinogen, renal functions, and lipid profiles in patients with SH and overt hypothyroid patients before and after LT4 treatment. Eleven healthy women were included in the study as a control group. Pretreatment Hcys levels were similar in SH and control subjects, whereas mean fibrinogen level of SH patients was higher than that of control subjects (p<0.05). Baseline Hcys (p<0.01) and fibrinogen (p<0.001) levels of the overt hypothyroid patients were significantly higher than those of the healthy subjects, and the pretreatment Hcys levels decreased with LT4 treatment (p<0.001). In conclusion, our data support that SH is not associated with hyperhomocysteinemia and Hcys does not appear to contribute to the increased risk for atherosclerotic disease in patients with SH.

摘要

本研究的目的是评估亚临床甲状腺功能减退(SH)和显性甲状腺功能减退患者在左甲状腺素(LT4)替代治疗前后的血浆总同型半胱氨酸(Hcys)和血清纤维蛋白原浓度,并与甲状腺功能正常的受试者进行比较。本研究招募了15名SH患者和20名甲状腺功能减退的绝经前女性。我们测量了SH患者和显性甲状腺功能减退患者在LT4治疗前后的空腹血浆Hcys水平、血清游离甲状腺素(fT4)、游离三碘甲状腺原氨酸(fT3)、促甲状腺激素(TSH)、叶酸、维生素B12、纤维蛋白原、肾功能和血脂谱。11名健康女性作为对照组纳入研究。SH患者和对照组受试者的治疗前Hcys水平相似,而SH患者的平均纤维蛋白原水平高于对照组(p<0.05)。显性甲状腺功能减退患者的基线Hcys(p<0.01)和纤维蛋白原(p<0.001)水平显著高于健康受试者,且LT4治疗后治疗前Hcys水平降低(p<0.001)。总之,我们的数据支持SH与高同型半胱氨酸血症无关,且Hcys似乎不会增加SH患者患动脉粥样硬化疾病的风险。

相似文献

4
8
Methimazole-induced hypothyroidism paradoxically decreases homocysteine.
Metabolism. 2005 Apr;54(4):460-5. doi: 10.1016/j.metabol.2004.10.013.
10
Homocysteine: a risk factor for cardiovascular disease in subclinical hypothyroidism?
Thyroid. 2002 Aug;12(8):733-6. doi: 10.1089/105072502760258721.

引用本文的文献

1
Vitamin B12 levels in thyroid disorders: A systematic review and meta-analysis.甲状腺疾病中的维生素 B12 水平:系统评价和荟萃分析。
Front Endocrinol (Lausanne). 2023 Feb 22;14:1070592. doi: 10.3389/fendo.2023.1070592. eCollection 2023.
2
Thyroid hormones and platelet activation in COVID-19 patients.COVID-19 患者的甲状腺激素与血小板活化。
J Endocrinol Invest. 2023 Feb;46(2):261-269. doi: 10.1007/s40618-022-01896-2. Epub 2022 Sep 5.

本文引用的文献

3
Homocysteine concentrations in subclinical hypothyroidism.
Endocr Res. 2004 Aug;30(3):351-9. doi: 10.1081/erc-200033558.
8
Homocysteine: a risk factor for cardiovascular disease in subclinical hypothyroidism?
Thyroid. 2002 Aug;12(8):733-6. doi: 10.1089/105072502760258721.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验